McKesson (MCK) Q4 Revenue Up 11.4% to $106.2B, EPS $9.34 vs Estimates

McKesson (NYSE:MCK) reported Q4 CY2025 revenue of $106.2 billion, up 11.4% year-on-year and in line with analyst expectations. Non-GAAP EPS of $9.34 was 0.7% above estimates. Supporting context: The company’s U.S. Pharmaceutical segment grew 13.6% YoY over the past two years. Sell-side analysts project 9.8% revenue growth for 2026. Q4 operating margin was 1.5%, while five-year average operating margin is 1.3%. McKesson’s five-year EPS CAGR was 18%, outpaced by a 22.4% share repurchase-driven reduction in shares outstanding. EPS is forecast to reach $37.58 for CY2026, up 14.2% from CY2025. The stock rose $2.1 to $839 following the results.